Finance

Lists
Q2 2027 earnings • in 1 day
See details
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
₹2,504.70
+4.02%
(+96.70) 1D
Nov 4, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
₹2,405.00
High
₹2,516.80
Low
₹2,380.10
Mkt. cap
706.89B
Avg. vol.
654.02K
Volume
717.67K
Dividend
0.20%
Quarterly dividend
₹1.25
Ex-dividend date
Oct 3, 2025
P/E ratio
39.33
52-wk high
₹2,537.60
52-wk low
₹1,801.40
EPS
₹63.68
Shares outstanding
0.00
No. of employees
17K
Open
₹2,405.00
High
₹2,516.80
Low
₹2,380.10
Mkt. cap
706.89B
Avg. vol.
654.02K
Volume
717.67K
Dividend
0.20%
Quarterly dividend
₹1.25
Ex-dividend date
Oct 3, 2025
P/E ratio
39.33
52-wk high
₹2,537.60
52-wk low
₹1,801.40
EPS
₹63.68
Shares outstanding
0.00
No. of employees
17K
News stories
From web sources and news partners
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. We unite scientific excellence, responsible execution and commercial agility to effectively address unmet patient needs of today and proactively anticipate the emerging health needs of tomorrow.The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees16.9K
Founded1977
Headquarters-
SectorPharmaceutical industry
Industry-
Websiteglenmarkpharma.com
Next call in 28:59:21
Thu, Nov 5, 10:00 PM
Fiscal period
Q2 2027
- / ₹15.60
Revenue / Est. (INR)
- / 41.10B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
60.47B
39.01B
38.31B
40.18B
Cost of goods sold
12.65B
12.95B
13.65B
12.46B
Cost of revenue
12.65B
12.95B
13.65B
12.46B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.86B
8.41B
16.49B
9.35B
Operating expense
25.64B
18.90B
17.91B
21.41B
Total operating expenses
38.29B
31.85B
31.56B
33.87B
Operating income
22.18B
7.15B
6.75B
6.32B
Other non operating income
2.01B
444.65M
-2.72B
657.64M
EBT including unusual items
9.67B
5.34B
3.88B
6.43B
EBT excluding unusual items
23.53B
7.18B
7.61B
6.43B
Income tax expense
3.57B
1.31B
864.49M
1.61B
Effective tax rate
36.90%
24.49%
22.29%
24.96%
Other operating expenses
13.37B
8.94B
-55.65M
10.33B
Net income
6.10B
4.03B
3.01B
4.83B
Net profit margin
10.09%
10.34%
7.87%
12.02%
Earnings per share
-
19.21
20.96
17.11
Interest and investment income
-
-
413.36M
-
Interest expense
-664.63M
-414.32M
-426.04M
-539.97M
Net interest expenses
-664.63M
-414.32M
-12.68M
-539.97M
Depreciation and amortization charges
1.41B
1.54B
1.48B
1.73B
EBITDA
23.54B
7.80B
7.80B
7.75B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps